CA2603920A1 - Traitement pharmacologique pour le traitement des apnees du sommeil - Google Patents

Traitement pharmacologique pour le traitement des apnees du sommeil Download PDF

Info

Publication number: CA2603920A1
Authority: CA; Canada
Prior art keywords: sleep; serotonin; ssri; receptor antagonist; apnea
Prior art date: 2005-04-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002603920A

Other languages

English (en)

Inventor

Miodrag Radulovacki

David W. Carley

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Illinois System

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-15

Filing date

2006-04-14

Publication date

2006-10-26

2006-04-14 Application filed by Individual filed Critical Individual

2006-10-26 Publication of CA2603920A1 publication Critical patent/CA2603920A1/fr

Status Abandoned legal-status Critical Current

Links

201000002859 sleep apnea Diseases 0.000 title claims description 58
238000011458 pharmacological treatment Methods 0.000 title description 10
230000007958 sleep Effects 0.000 claims abstract description 79
230000029058 respiratory gaseous exchange Effects 0.000 claims abstract description 53
238000000034 method Methods 0.000 claims abstract description 22
229960005343 ondansetron Drugs 0.000 claims description 68
239000003420 antiserotonin agent Substances 0.000 claims description 55
229940121356 serotonin receptor antagonist Drugs 0.000 claims description 54
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 41
239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 41
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
208000035475 disorder Diseases 0.000 claims description 34
208000001797 obstructive sleep apnea Diseases 0.000 claims description 34
239000000203 mixture Substances 0.000 claims description 29
238000011282 treatment Methods 0.000 claims description 29
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 15
229960002464 fluoxetine Drugs 0.000 claims description 13
239000003814 drug Substances 0.000 claims description 8
206010008501 Cheyne-Stokes respiration Diseases 0.000 claims description 5
206010041235 Snoring Diseases 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
208000020112 Apnea of prematurity Diseases 0.000 claims description 2
206010066131 Congenital central hypoventilation syndrome Diseases 0.000 claims description 2
208000004166 Obesity Hypoventilation Syndrome Diseases 0.000 claims description 2
206010035004 Pickwickian syndrome Diseases 0.000 claims description 2
208000014486 central sleep apnea syndrome Diseases 0.000 claims description 2
FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims 3
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract description 176
229940076279 serotonin Drugs 0.000 abstract description 78
230000002265 prevention Effects 0.000 abstract description 8
230000000144 pharmacologic effect Effects 0.000 abstract description 7
208000008784 apnea Diseases 0.000 description 93
230000000694 effects Effects 0.000 description 69
FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 54
239000003795 chemical substances by application Substances 0.000 description 49
241001465754 Metazoa Species 0.000 description 35
230000036385 rapid eye movement (rem) sleep Effects 0.000 description 32
230000037053 non-rapid eye movement Effects 0.000 description 31
208000003417 Central Sleep Apnea Diseases 0.000 description 21
230000000241 respiratory effect Effects 0.000 description 21
230000001965 increasing effect Effects 0.000 description 19
230000002269 spontaneous effect Effects 0.000 description 19
102000005962 receptors Human genes 0.000 description 18
108020003175 receptors Proteins 0.000 description 18
FELGMEQIXOGIFQ-ZDUSSCGKSA-N (3s)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-ZDUSSCGKSA-N 0.000 description 16
230000036772 blood pressure Effects 0.000 description 16
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 15
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 15
230000004461 rapid eye movement Effects 0.000 description 15
241000700159 Rattus Species 0.000 description 14
230000001629 suppression Effects 0.000 description 14
239000000952 serotonin receptor agonist Substances 0.000 description 12
150000001875 compounds Chemical class 0.000 description 11
210000001428 peripheral nervous system Anatomy 0.000 description 11
230000002093 peripheral effect Effects 0.000 description 10
230000000862 serotonergic effect Effects 0.000 description 10
239000000674 adrenergic antagonist Substances 0.000 description 9
230000008901 benefit Effects 0.000 description 9
210000003169 central nervous system Anatomy 0.000 description 9
238000001356 surgical procedure Methods 0.000 description 9
238000009423 ventilation Methods 0.000 description 9
102000035037 5-HT3 receptors Human genes 0.000 description 8
108091005477 5-HT3 receptors Proteins 0.000 description 8
230000008485 antagonism Effects 0.000 description 8
230000000414 obstructive effect Effects 0.000 description 8
238000012360 testing method Methods 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
230000003042 antagnostic effect Effects 0.000 description 7
-1 for example Chemical class 0.000 description 7
239000007924 injection Substances 0.000 description 7
238000002347 injection Methods 0.000 description 7
238000007912 intraperitoneal administration Methods 0.000 description 7
230000000306 recurrent effect Effects 0.000 description 7
210000003625 skull Anatomy 0.000 description 7
238000007910 systemic administration Methods 0.000 description 7
230000009471 action Effects 0.000 description 6
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
238000000540 analysis of variance Methods 0.000 description 6
DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 6
239000002243 precursor Substances 0.000 description 6
230000009467 reduction Effects 0.000 description 6
230000004044 response Effects 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 6
208000011580 syndromic disease Diseases 0.000 description 6
229940113081 5 Hydroxytryptamine 3 receptor antagonist Drugs 0.000 description 5
102000017462 5-hydroxytryptamine 3 receptors Human genes 0.000 description 5
108050005670 5-hydroxytryptamine 3 receptors Proteins 0.000 description 5
206010021133 Hypoventilation Diseases 0.000 description 5
206010041349 Somnolence Diseases 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
230000008499 blood brain barrier function Effects 0.000 description 5
210000001218 blood-brain barrier Anatomy 0.000 description 5
QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 5
229960002495 buspirone Drugs 0.000 description 5
229940079593 drug Drugs 0.000 description 5
230000002526 effect on cardiovascular system Effects 0.000 description 5
238000001990 intravenous administration Methods 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
229940044551 receptor antagonist Drugs 0.000 description 5
239000002464 receptor antagonist Substances 0.000 description 5
230000036387 respiratory rate Effects 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
241000282326 Felis catus Species 0.000 description 4
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
210000000709 aorta Anatomy 0.000 description 4
108091008690 chemoreceptors Proteins 0.000 description 4
229960005132 cisapride Drugs 0.000 description 4
DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
239000007943 implant Substances 0.000 description 4
238000002513 implantation Methods 0.000 description 4
RHCSKNNOAZULRK-UHFFFAOYSA-N mescaline Chemical compound COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 description 4
210000003205 muscle Anatomy 0.000 description 4
230000000422 nocturnal effect Effects 0.000 description 4
210000000584 nodose ganglion Anatomy 0.000 description 4
OMLDMGPCWMBPAN-YPMHNXCESA-N norcisapride Chemical compound CO[C@H]1CNCC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC OMLDMGPCWMBPAN-YPMHNXCESA-N 0.000 description 4
239000002831 pharmacologic agent Substances 0.000 description 4
230000002618 waking effect Effects 0.000 description 4
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 3
KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 3
WYWNEDARFVJQSG-UHFFFAOYSA-N 2-methylserotonin Chemical compound C1=C(O)C=C2C(CCN)=C(C)NC2=C1 WYWNEDARFVJQSG-UHFFFAOYSA-N 0.000 description 3
229940122230 5 Hydroxytryptamine 2 receptor agonist Drugs 0.000 description 3
ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 3
108060003345 Adrenergic Receptor Proteins 0.000 description 3
102000017910 Adrenergic receptor Human genes 0.000 description 3
206010003497 Asphyxia Diseases 0.000 description 3
239000002126 C01EB10 - Adenosine Substances 0.000 description 3
208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 3
241000282412 Homo Species 0.000 description 3
241000282414 Homo sapiens Species 0.000 description 3
206010020772 Hypertension Diseases 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 3
206010062519 Poor quality sleep Diseases 0.000 description 3
230000004913 activation Effects 0.000 description 3
229960005305 adenosine Drugs 0.000 description 3
239000000556 agonist Substances 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
238000010171 animal model Methods 0.000 description 3
229940082988 antihypertensives serotonin antagonists Drugs 0.000 description 3
230000003542 behavioural effect Effects 0.000 description 3
210000000133 brain stem Anatomy 0.000 description 3
SPKBYQZELVEOLL-QDMKHBRRSA-N chembl2111147 Chemical class N([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C1=CC(Cl)=CC2=C1OC(C)(C)C2 SPKBYQZELVEOLL-QDMKHBRRSA-N 0.000 description 3
230000001054 cortical effect Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000012458 free base Substances 0.000 description 3
208000017883 infantile apnea Diseases 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 3
229960001186 methysergide Drugs 0.000 description 3
238000012544 monitoring process Methods 0.000 description 3
239000002858 neurotransmitter agent Substances 0.000 description 3
230000001936 parietal effect Effects 0.000 description 3
229960002296 paroxetine Drugs 0.000 description 3
230000035790 physiological processes and functions Effects 0.000 description 3
230000001242 postsynaptic effect Effects 0.000 description 3
230000003518 presynaptic effect Effects 0.000 description 3
229940044601 receptor agonist Drugs 0.000 description 3
239000000018 receptor agonist Substances 0.000 description 3
230000011514 reflex Effects 0.000 description 3
230000008667 sleep stage Effects 0.000 description 3
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
230000001052 transient effect Effects 0.000 description 3
230000001515 vagal effect Effects 0.000 description 3
210000001186 vagus nerve Anatomy 0.000 description 3
VZVRZTZPHOHSCK-YVLHZVERSA-N (3z)-3-(12h-[1]benzofuro[3,2-c][1]benzoxepin-6-ylidene)-n,n-dimethylpropan-1-amine Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=C1C1=CC=CC=C1O2 VZVRZTZPHOHSCK-YVLHZVERSA-N 0.000 description 2
FAVUCMGCKDICCE-UHFFFAOYSA-N (8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl) 1h-indole-3-carboxylate;iodide Chemical compound [I-].C1=CC=C2C(C(=O)OC3CC4CCC(C3)[N+]4(C)C)=CNC2=C1 FAVUCMGCKDICCE-UHFFFAOYSA-N 0.000 description 2
DYJVZTAMQYDCLP-VCSAJMHUSA-N (z)-but-2-enedioic acid;3-hydroxybutan-2-yl (6ar,9r,10ar)-7-methyl-4-propan-2-yl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-9-carboxylate Chemical compound OC(=O)\C=C/C(O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)OC(C)C(O)C)=C3C2=CN(C(C)C)C3=C1 DYJVZTAMQYDCLP-VCSAJMHUSA-N 0.000 description 2
TZJUVVIWVWFLCD-UHFFFAOYSA-N 1,1-dioxo-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzothiazol-3-one Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 TZJUVVIWVWFLCD-UHFFFAOYSA-N 0.000 description 2
VHFVKMTVMIZMIK-UHFFFAOYSA-N 1-(3-chlorophenyl)piperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1 VHFVKMTVMIZMIK-UHFFFAOYSA-N 0.000 description 2
WEUCDJCFJHYFRL-UHFFFAOYSA-N 1-[(4-chlorophenyl)-phenylmethyl]-4-methyl-1,4-diazepane Chemical compound C1CN(C)CCCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 WEUCDJCFJHYFRL-UHFFFAOYSA-N 0.000 description 2
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
PYJBJMIBANAOFJ-UHFFFAOYSA-N 1-[5-(thiophen-2-ylmethoxy)-1h-indol-3-yl]propan-2-amine;hydrochloride Chemical compound Cl.C1=C2C(CC(N)C)=CNC2=CC=C1OCC1=CC=CS1 PYJBJMIBANAOFJ-UHFFFAOYSA-N 0.000 description 2
SAJKHRHHDGSJEZ-UHFFFAOYSA-N 2-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-4,4-dimethylisoquinoline-1,3-dione;dihydrochloride Chemical compound Cl.Cl.COC1=CC=CC=C1N1CCN(CCN2C(C(C)(C)C3=CC=CC=C3C2=O)=O)CC1 SAJKHRHHDGSJEZ-UHFFFAOYSA-N 0.000 description 2
ZDLILMQNLSEPLK-UHFFFAOYSA-N 2-chloro-5-methoxy-n-piperidin-4-ylpyrimidin-4-amine Chemical compound COC1=CN=C(Cl)N=C1NC1CCNCC1 ZDLILMQNLSEPLK-UHFFFAOYSA-N 0.000 description 2
FPDIERBPQFAFSI-UHFFFAOYSA-N 2-hydroxymethylolanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(CO)S2 FPDIERBPQFAFSI-UHFFFAOYSA-N 0.000 description 2
JXZZEXZZKAWDSP-UHFFFAOYSA-N 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole Chemical compound C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1NC(=O)C1=CC=CC=C1 JXZZEXZZKAWDSP-UHFFFAOYSA-N 0.000 description 2
VXVWIFPRBAAZEY-KOEKDOOYSA-N 3-[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-1-yl]indole-3-carboxylic acid Chemical compound C1=NC2=CC=CC=C2C1(C(O)=O)[C@]1(CCC2)CC[C@@H]2N1C VXVWIFPRBAAZEY-KOEKDOOYSA-N 0.000 description 2
FHPIXVHJEIZKJW-UHFFFAOYSA-N 4'-N-desmethylolanzapine Chemical compound S1C(C)=CC2=C1NC1=CC=CC=C1N=C2N1CCNCC1 FHPIXVHJEIZKJW-UHFFFAOYSA-N 0.000 description 2
FFNWMBDISAYHDC-UHFFFAOYSA-N 4-amino-5-chloro-2-methoxybenzoic acid 2-(diethylamino)ethyl ester Chemical compound CCN(CC)CCOC(=O)C1=CC(Cl)=C(N)C=C1OC FFNWMBDISAYHDC-UHFFFAOYSA-N 0.000 description 2
229940122969 5 Hydroxytryptamine 2 receptor antagonist Drugs 0.000 description 2
101000742062 Bos taurus Protein phosphatase 1G Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
206010021079 Hypopnoea Diseases 0.000 description 2
206010021143 Hypoxia Diseases 0.000 description 2
RLJFTICUTYVZDG-UHFFFAOYSA-N Methiothepine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2CC1N1CCN(C)CC1 RLJFTICUTYVZDG-UHFFFAOYSA-N 0.000 description 2
UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 2
HKXMQLISPYELRD-UHFFFAOYSA-N N-[4-[[5-[3-(2-aminoethyl)-1H-indol-5-yl]-1,2,4-oxadiazol-3-yl]methyl]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1CC1=NOC(C=2C=C3C(CCN)=CNC3=CC=2)=N1 HKXMQLISPYELRD-UHFFFAOYSA-N 0.000 description 2
SJDOMIRMMUGQQK-UHFFFAOYSA-N NAN 190 Chemical compound COC1=CC=CC=C1N1CCN(CCCCN2C(C3=CC=CC=C3C2=O)=O)CC1 SJDOMIRMMUGQQK-UHFFFAOYSA-N 0.000 description 2
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
PWRPUAKXMQAFCJ-UHFFFAOYSA-N Perlapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2CC2=CC=CC=C12 PWRPUAKXMQAFCJ-UHFFFAOYSA-N 0.000 description 2
QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 2
QJQORSLQNXDVGE-UHFFFAOYSA-N SB 206553 Chemical compound C1CC=2C=C3N(C)C=CC3=CC=2N1C(=O)NC1=CC=CN=C1 QJQORSLQNXDVGE-UHFFFAOYSA-N 0.000 description 2
208000032140 Sleepiness Diseases 0.000 description 2
208000001871 Tachycardia Diseases 0.000 description 2
BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
230000001270 agonistic effect Effects 0.000 description 2
230000001668 ameliorated effect Effects 0.000 description 2
230000037007 arousal Effects 0.000 description 2
BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
208000006218 bradycardia Diseases 0.000 description 2
230000036471 bradycardia Effects 0.000 description 2
210000001011 carotid body Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 2
229960001076 chlorpromazine Drugs 0.000 description 2
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
RSUVYMGADVXGOU-BUHFOSPRSA-N cinanserin Chemical compound CN(C)CCCSC1=CC=CC=C1NC(=O)\C=C\C1=CC=CC=C1 RSUVYMGADVXGOU-BUHFOSPRSA-N 0.000 description 2
229950001684 cinanserin Drugs 0.000 description 2
229960004170 clozapine Drugs 0.000 description 2
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 2
229960001140 cyproheptadine Drugs 0.000 description 2
150000004683 dihydrates Chemical class 0.000 description 2
229960003413 dolasetron Drugs 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
229960001389 doxazosin Drugs 0.000 description 2
RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 2
230000000517 effect on sleep Effects 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
229960000647 gepirone Drugs 0.000 description 2
QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 description 2
229960003878 haloperidol Drugs 0.000 description 2
229950008315 homochlorcyclizine Drugs 0.000 description 2
208000018875 hypoxemia Diseases 0.000 description 2
230000006872 improvement Effects 0.000 description 2
229960002056 indoramin Drugs 0.000 description 2
230000006698 induction Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
229950003599 ipsapirone Drugs 0.000 description 2
229960005417 ketanserin Drugs 0.000 description 2
229960000423 loxapine Drugs 0.000 description 2
XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 2
MLWGAEVSWJXOQJ-UHFFFAOYSA-N mdl 74156 Chemical compound C1=CC=C2C(C(=O)OC3CC4N5CC(C(CC5C3)C4)O)=CNC2=C1 MLWGAEVSWJXOQJ-UHFFFAOYSA-N 0.000 description 2
WZHJKEUHNJHDLS-QTGUNEKASA-N metergoline Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4N(C)C=C(C=34)C2)C1)C)NC(=O)OCC1=CC=CC=C1 WZHJKEUHNJHDLS-QTGUNEKASA-N 0.000 description 2
229960004650 metergoline Drugs 0.000 description 2
229960003955 mianserin Drugs 0.000 description 2
239000003887 narcotic antagonist Substances 0.000 description 2
210000004237 neck muscle Anatomy 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
238000012316 non-parametric ANOVA Methods 0.000 description 2
229960005017 olanzapine Drugs 0.000 description 2
KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
238000001543 one-way ANOVA Methods 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
229960003544 oxetorone Drugs 0.000 description 2
239000008188 pellet Substances 0.000 description 2
230000000737 periodic effect Effects 0.000 description 2
229950009253 perlapine Drugs 0.000 description 2
229960003418 phenoxybenzamine Drugs 0.000 description 2
229960001999 phentolamine Drugs 0.000 description 2
MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 2
230000035479 physiological effects, processes and functions Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
229960001289 prazosin Drugs 0.000 description 2
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 2
ISYORFGKSZLPNW-UHFFFAOYSA-N propan-2-ylazanium;chloride Chemical compound [Cl-].CC(C)[NH3+] ISYORFGKSZLPNW-UHFFFAOYSA-N 0.000 description 2
150000003242 quaternary ammonium salts Chemical group 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
210000003019 respiratory muscle Anatomy 0.000 description 2
239000003169 respiratory stimulant agent Substances 0.000 description 2
RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 2
229960001534 risperidone Drugs 0.000 description 2
JUQLTPCYUFPYKE-UHFFFAOYSA-N ritanserin Chemical compound CC=1N=C2SC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 JUQLTPCYUFPYKE-UHFFFAOYSA-N 0.000 description 2
229950009626 ritanserin Drugs 0.000 description 2
229960000425 rizatriptan Drugs 0.000 description 2
TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 description 2
239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 description 2
230000037321 sleepiness Effects 0.000 description 2
230000037322 slow-wave sleep Effects 0.000 description 2
IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 2
210000004872 soft tissue Anatomy 0.000 description 2
239000000243 solution Substances 0.000 description 2
241000894007 species Species 0.000 description 2
238000013222 sprague-dawley male rat Methods 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 2
229960003708 sumatriptan Drugs 0.000 description 2
VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 2
229960001693 terazosin Drugs 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
229960002312 tolazoline Drugs 0.000 description 2
JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 description 2
229960002906 trimazosin Drugs 0.000 description 2
YNZXWQJZEDLQEG-UHFFFAOYSA-N trimazosin Chemical compound N1=C2C(OC)=C(OC)C(OC)=CC2=C(N)N=C1N1CCN(C(=O)OCC(C)(C)O)CC1 YNZXWQJZEDLQEG-UHFFFAOYSA-N 0.000 description 2
229960003688 tropisetron Drugs 0.000 description 2
UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 2
229960000317 yohimbine Drugs 0.000 description 2
AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 2
229950005255 zalospirone Drugs 0.000 description 2
AERLHOTUXIJQFV-RCPZPFRWSA-N zalospirone Chemical compound O=C([C@@H]1[C@@H]([C@@H]2C=C[C@H]1[C@H]1C=C[C@H]12)C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 AERLHOTUXIJQFV-RCPZPFRWSA-N 0.000 description 2
229950001074 zatosetron Drugs 0.000 description 2
229960001360 zolmitriptan Drugs 0.000 description 2
UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
XFDJYSQDBULQSI-QFIPXVFZSA-N (R)-doxapram Chemical compound C([C@H]1CN(C(C1(C=1C=CC=CC=1)C=1C=CC=CC=1)=O)CC)CN1CCOCC1 XFDJYSQDBULQSI-QFIPXVFZSA-N 0.000 description 1
RTHCYVBBDHJXIQ-INIZCTEOSA-N (S)-fluoxetine Chemical compound O([C@@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-INIZCTEOSA-N 0.000 description 1
PNVNVHUZROJLTJ-INIZCTEOSA-N 1-[(1r)-2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol Chemical compound C1=CC(OC)=CC=C1[C@H](CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-INIZCTEOSA-N 0.000 description 1
PNVNVHUZROJLTJ-MRXNPFEDSA-N 1-[(1s)-2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol Chemical compound C1=CC(OC)=CC=C1[C@@H](CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-MRXNPFEDSA-N 0.000 description 1
229940119151 5 Hydroxytryptamine 3 receptor agonist Drugs 0.000 description 1
229940127239 5 Hydroxytryptamine receptor antagonist Drugs 0.000 description 1
102000011352 5-Hydroxytryptamine 2A receptors Human genes 0.000 description 1
108050001673 5-Hydroxytryptamine 2A receptors Proteins 0.000 description 1
102000009394 5-Hydroxytryptamine 2C receptors Human genes 0.000 description 1
108050000259 5-Hydroxytryptamine 2C receptors Proteins 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
208000002381 Brain Hypoxia Diseases 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 1
229920003043 Cellulose fiber Polymers 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
229920001651 Cyanoacrylate Polymers 0.000 description 1
PTJADDMMFYXMMG-UHFFFAOYSA-N Demethylcitalopram Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCNC)C1=CC=C(F)C=C1 PTJADDMMFYXMMG-UHFFFAOYSA-N 0.000 description 1
241001269524 Dura Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
206010020591 Hypercapnia Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
206010024119 Left ventricular failure Diseases 0.000 description 1
206010025391 Macroglossia Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
206010027590 Middle insomnia Diseases 0.000 description 1
YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
208000034888 Needle issue Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000008601 Polycythemia Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
208000004756 Respiratory Insufficiency Diseases 0.000 description 1
206010051821 Retrognathia Diseases 0.000 description 1
206010039203 Road traffic accident Diseases 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
210000003815 abdominal wall Anatomy 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
229960005054 acepromazine Drugs 0.000 description 1
NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
229960000571 acetazolamide Drugs 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
150000003838 adenosines Chemical class 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
239000002269 analeptic agent Substances 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
230000002567 autonomic effect Effects 0.000 description 1
108091008698 baroreceptors Proteins 0.000 description 1
239000002585 base Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
230000007177 brain activity Effects 0.000 description 1
244000309464 bull Species 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
230000002802 cardiorespiratory effect Effects 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229960001653 citalopram Drugs 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
239000003479 dental cement Substances 0.000 description 1
SRPXSILJHWNFMK-ZBEGNZNMSA-N desmethylsertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)N)=CC=C(Cl)C(Cl)=C1 SRPXSILJHWNFMK-ZBEGNZNMSA-N 0.000 description 1
238000011161 development Methods 0.000 description 1
230000003205 diastolic effect Effects 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229960002955 doxapram Drugs 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
238000002567 electromyography Methods 0.000 description 1
JJJFUHOGVZWXNQ-UHFFFAOYSA-N enbucrilate Chemical compound CCCCOC(=O)C(=C)C#N JJJFUHOGVZWXNQ-UHFFFAOYSA-N 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
238000010304 firing Methods 0.000 description 1
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
229960004038 fluvoxamine Drugs 0.000 description 1
210000004055 fourth ventricle Anatomy 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
229960003727 granisetron Drugs 0.000 description 1
MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
230000002650 habitual effect Effects 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
208000000122 hyperventilation Diseases 0.000 description 1
230000000870 hyperventilation Effects 0.000 description 1
230000002990 hypoglossal effect Effects 0.000 description 1
201000001881 impotence Diseases 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
230000001788 irregular Effects 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
229960004616 medroxyprogesterone Drugs 0.000 description 1
230000006984 memory degeneration Effects 0.000 description 1
208000023060 memory loss Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229960000600 milnacipran Drugs 0.000 description 1
UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
235000007708 morin Nutrition 0.000 description 1
BMGVVCPMFGMQEM-UHFFFAOYSA-N n-[3-[[5-[3-(2-aminoethyl)-1h-indol-5-yl]-1,2,4-oxadiazol-3-yl]methyl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(CC=2N=C(ON=2)C=2C=C3C(CCN)=CNC3=CC=2)=C1 BMGVVCPMFGMQEM-UHFFFAOYSA-N 0.000 description 1
229960004127 naloxone Drugs 0.000 description 1
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
229960001800 nefazodone Drugs 0.000 description 1
VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
230000002232 neuromuscular Effects 0.000 description 1
208000018360 neuromuscular disease Diseases 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
WIQRCHMSJFFONW-UHFFFAOYSA-N norfluoxetine Chemical compound C=1C=CC=CC=1C(CCN)OC1=CC=C(C(F)(F)F)C=C1 WIQRCHMSJFFONW-UHFFFAOYSA-N 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
239000003401 opiate antagonist Substances 0.000 description 1
210000003300 oropharynx Anatomy 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
238000007427 paired t-test Methods 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
210000004197 pelvis Anatomy 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
210000001774 pressoreceptor Anatomy 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
229960002601 protriptyline Drugs 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
208000002815 pulmonary hypertension Diseases 0.000 description 1
238000005956 quaternization reaction Methods 0.000 description 1
210000002254 renal artery Anatomy 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
239000003829 resin cement Substances 0.000 description 1
201000004193 respiratory failure Diseases 0.000 description 1
238000012552 review Methods 0.000 description 1
231100000817 safety factor Toxicity 0.000 description 1
238000012216 screening Methods 0.000 description 1
229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
239000003772 serotonin uptake inhibitor Substances 0.000 description 1
229960002073 sertraline Drugs 0.000 description 1
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
229960004425 sibutramine Drugs 0.000 description 1
230000011664 signaling Effects 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
208000022925 sleep disturbance Diseases 0.000 description 1
235000013024 sodium fluoride Nutrition 0.000 description 1
239000011775 sodium fluoride Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000002782 sympathoadrenal effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
239000003106 tissue adhesive Substances 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
229960004799 tryptophan Drugs 0.000 description 1
238000007492 two-way ANOVA Methods 0.000 description 1
229960004688 venlafaxine Drugs 0.000 description 1
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
230000003519 ventilatory effect Effects 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
206010047302 ventricular tachycardia Diseases 0.000 description 1
238000012800 visualization Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002603920A 2005-04-15 2006-04-14 Traitement pharmacologique pour le traitement des apnees du sommeil Abandoned CA2603920A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US67216805P	2005-04-15	2005-04-15
US60/672,168		2005-04-15
PCT/US2006/014099 WO2006113448A1 (fr)	2005-04-15	2006-04-14	Traitement pharmacologique pour le traitement des apnees du sommeil

Publications (1)

Publication Number	Publication Date
CA2603920A1 true CA2603920A1 (fr)	2006-10-26

Family

ID=36757052

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002603920A Abandoned CA2603920A1 (fr)	2005-04-15	2006-04-14	Traitement pharmacologique pour le traitement des apnees du sommeil

Country Status (4)

Country	Link
EP (1)	EP1868602A1 (fr)
AU (1)	AU2006236602B2 (fr)
CA (1)	CA2603920A1 (fr)
WO (1)	WO2006113448A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112020015316A2 (pt)	2018-01-30	2020-12-08	Apnimed, Inc. (Delaware)	Métodos e composições para o tratamento da apneia do sono

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7160898B2 (en) *	2001-12-14	2007-01-09	Board Of Trustees Of The University Of Illinois	Pharmacological treatment for sleep apnea
US6986901B2 (en) *	2002-07-15	2006-01-17	Warner-Lambert Company Llc	Gastrointestinal compositions
CN101132777A (zh) *	2004-12-20	2008-02-27	科利吉姆制药公司	用于睡眠障碍的药物组合物

2006
- 2006-04-14 CA CA002603920A patent/CA2603920A1/fr not_active Abandoned
- 2006-04-14 AU AU2006236602A patent/AU2006236602B2/en not_active Ceased
- 2006-04-14 EP EP06740950A patent/EP1868602A1/fr not_active Withdrawn
- 2006-04-14 WO PCT/US2006/014099 patent/WO2006113448A1/fr not_active Ceased

Also Published As

Publication number	Publication date
AU2006236602B2 (en)	2011-10-13
AU2006236602A1 (en)	2006-10-26
WO2006113448A1 (fr)	2006-10-26
EP1868602A1 (fr)	2007-12-26

Publication	Publication Date	Title
CA2321900C (fr)	2011-07-19	Agents presentant une activite de type serotonine pour le traitement des apnees du sommeil
US20120108570A1 (en)	2012-05-03	Pharmacological Treatment for Sleep Apnea
CA2443105C (fr)	2011-11-08	Role fonctionnel des cannabinoides sur la stabilite autonome pendant le sommeil
AU2002309548A1 (en)	2003-04-10	Functional role for cannabinoids in autonomic stability during sleep
US20120010198A1 (en)	2012-01-12	Methods for Treating Sleep Disorders by Cholecystokinin (CCK) Receptor B Antagonists
US20090221658A1 (en)	2009-09-03	Pharmacological Treatment for Sleep Apnea
AU2006236602B2 (en)	2011-10-13	Pharmacological treatment for sleep apnea

Legal Events

Date	Code	Title	Description
2011-04-05	EEER	Examination request
2014-02-24	FZDE	Dead	Effective date: 20131230